Premier Perspectives The blog for insider insights in clinical development Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseLife at Premier By functional area All functional areas Development StrategyClinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Study Design Just How Big is the Placebo Problem? By Scott Millard April 6, 2018 Clinical ResearchPhase 1 - Phase 4 CAR T-cell Therapies: Safety Considerations and Toxicity Management By Premier Research March 23, 2018 Medical and Regulatory Affairs The Regulatory Landscape for Immuno-gene Therapeutics in Hematological Malignances By Colin Hayward March 15, 2018 Medical and Regulatory Affairs Learning to Listen: Voice of the Patient Grows Louder in Product Development By Juliet Moritz March 13, 2018 Clinical ResearchPhase 1 - Phase 4 Better Days Ahead? The Emerging State of CNS Drug Development By Krista Armstrong March 8, 2018 Clinical ResearchPhase 1 - Phase 4 Why Forecasting Trial Costs Is So Hard (and Getting Harder) By Daryl Fallon March 5, 2018 Previous 1 …33 34 35 36 37 … 57 Next × ALSO OF INTERESTKey Considerations When Designing a Phase 1...Nostalgia or Shell Shock? Assessing PTSD Is a...Gene Therapy 101: From the 1960s to Today